In neurological diseases, the actions of microglia, the resident myeloid cells of the CNS
parenchyma, may diverge from, or intersect with, those of recruited monocytes to drive …

In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …

Importance In multiple sclerosis (MS), chronic active lesions, which previously could only be
detected at autopsy, can now be identified on susceptibility-based magnetic resonance …

The pathogenetic mechanisms underlying neuronal death and dysfunction in Alzheimer's
disease (AD) remain unclear. However, chronic neuroinflammation has been implicated in …

Alzheimer's disease (AD) is considered a polygenic disorder. This view is clouded, however,
by lingering uncertainty over how to treat the quasi" monogenic" role of apolipoprotein E …

Fatigue is one of the most common symptoms in multiple sclerosis (MS), with a major impact
on patients' quality of life. Currently, treatment proceeds by trial and error with limited …

Multiple sclerosis is a complex and heterogeneous, most likely autoimmune, demyelinating
disease of the central nervous system (CNS). Although a number of histological …

Objective: To examine the effects of disease activity, disability, and disease-modifying
therapies (DMTs) on serum neurofilament light (NFL) and the correlation between NFL …

Abstract See Stankoff and Louapre (doi: 10.1093/brain/awy114) for a scientific commentary
on this article. Grey matter atrophy is present from the earliest stages of multiple sclerosis …

The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing
owing to increased longevity of the general population and the availability of effective …